We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


ERS Genomics Announces Agreement With Applied StemCell To Commercialize CRISPR Gene Editing Solutions

Want a FREE PDF version of this product news?

Complete the form below and we will email you a PDF version of "ERS Genomics Announces Agreement With Applied StemCell To Commercialize CRISPR Gene Editing Solutions"

Listen with
Register for FREE to listen to this article
Thank you. Listen to this article using the player above.
Read time:

ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property (IP) co-owned by Dr Emmanuelle Charpentier, announced on the 15th September that it has signed an agreement with Applied StemCell, Inc., a leading provider of stem cell, animal model, antibody discovery services and reagents.

ERS Genomics holds an exclusive worldwide license from Dr. Charpentier to the foundational patents covering CRISPR/Cas9. Companies can obtain licenses to this technology for internal research and commercialization of research tools, kits, reagents and genetically modified cell lines and organisms.

Applied StemCell is a fast growing California based biotech company with a goal of advancing gene editing and stem cell innovation worldwide. Applied StemCell offers a wide variety of preclinical research services including cell and animal model generation, antibody discovery, and preclinical assay services to support cell/gene product development.

Eric Rhodes, CEO of ERS Genomics stated: “It is exciting to see their expertise in cell and animal models being combined with the power of CRISPR gene editing."

Ruby Tsai, CEO of Applied StemCell added: “We are extremely excited to build on the strength of our existing platform while investing our R&D in emerging technologies to drive our future growth,” 

Financial details of the agreement are not disclosed.